These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 25179689

  • 1. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H, Cooper W, O'Boyle E, Gabrail N, Boccia R, Gralla RJ.
    Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R, O'Boyle E, Cooper W.
    BMC Cancer; 2016 Feb 26; 16():166. PubMed ID: 26921245
    [Abstract] [Full Text] [Related]

  • 3. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
    Raftopoulos H, Boccia R, Cooper W, O'Boyle E, Gralla RJ.
    Future Oncol; 2015 Sep 26; 11(18):2541-51. PubMed ID: 26289588
    [Abstract] [Full Text] [Related]

  • 4. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N.
    Cochrane Database Syst Rev; 2021 Nov 16; 11(11):CD012775. PubMed ID: 34784425
    [Abstract] [Full Text] [Related]

  • 5. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 16; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 6. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM, Kim HJ, Choi YJ, Lee EM, Kim YS, Oh SY, Koh SJ, Baek JH, Lee WS, Joo YD, Lee HG, Yun EY, Chung JS.
    Support Care Cancer; 2016 Feb 16; 24(2):945-952. PubMed ID: 26265119
    [Abstract] [Full Text] [Related]

  • 7. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP, Scott LJ.
    Drugs; 2009 Nov 12; 69(16):2257-78. PubMed ID: 19852528
    [Abstract] [Full Text] [Related]

  • 8. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
    Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL.
    Future Oncol; 2016 Jun 12; 12(12):1469-81. PubMed ID: 26997579
    [Abstract] [Full Text] [Related]

  • 9. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
    Vacirca J, Caruana D, Calcanes G, Mosier M, Boccia R, McBride A.
    Future Oncol; 2018 Jun 12; 14(14):1387-1396. PubMed ID: 29421926
    [Abstract] [Full Text] [Related]

  • 10. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
    Boccia R, Cooper W, O'Boyle E.
    J Community Support Oncol; 2015 Feb 12; 13(2):38-46. PubMed ID: 25866983
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.
    Support Care Cancer; 2013 May 12; 21(5):1453-60. PubMed ID: 23354552
    [Abstract] [Full Text] [Related]

  • 12. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 13. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Deeks ED.
    Drugs; 2016 Dec 01; 76(18):1779-1786. PubMed ID: 27915445
    [Abstract] [Full Text] [Related]

  • 14. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
    van der Vorst MJDL, Toffoli EC, Beusink M, van Linde ME, van Voorthuizen T, Brouwer S, van Zweeden AA, Vrijaldenhoven S, Berends JC, Berkhof J, Verheul HMW.
    Oncologist; 2021 Jan 01; 26(1):e173-e181. PubMed ID: 32735029
    [Abstract] [Full Text] [Related]

  • 15. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M.
    Ann Oncol; 2018 Feb 01; 29(2):452-458. PubMed ID: 29092012
    [Abstract] [Full Text] [Related]

  • 16. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A.
    Ann Oncol; 2006 Sep 01; 17(9):1441-9. PubMed ID: 16766588
    [Abstract] [Full Text] [Related]

  • 17. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron.
    Ottoboni T, Gelder MS, O'Boyle E.
    J Exp Pharmacol; 2014 Sep 01; 6():15-21. PubMed ID: 27186139
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M, A El-Azab G, A Tawfik H.
    Cancer Chemother Pharmacol; 2021 Jul 01; 88(1):121-129. PubMed ID: 33835230
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M.
    Ann Oncol; 2003 Oct 01; 14(10):1570-7. PubMed ID: 14504060
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
    Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M.
    Int J Clin Oncol; 2015 Dec 01; 20(6):1051-6. PubMed ID: 25822106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.